II期试验-话题@MedSci

#II期试验#

98篇内容 | 2699人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1947713, encodeId=6f8a194e7134b, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=JCO：PROSTVAC在转移性去势抵抗性前列腺癌中的III期试验, objectType=article, longId=161545, objectId=3b1a161545a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b1a161545a9, replyNumber=0, likeNumber=57, createdTime=2019-11-18, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b1a161545a9, moduleTitle=JCO：PROSTVAC在转移性去势抵抗性前列腺癌中的III期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b1a161545a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947718, encodeId=140f194e7182b, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=诺华的吸入型联合疗法QMF149治疗哮喘III期试验达到实验终点, objectType=article, longId=167489, objectId=a85316e489c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a85316e489c3, replyNumber=0, likeNumber=77, createdTime=2019-10-08, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a85316e489c3, moduleTitle=诺华的吸入型联合疗法QMF149治疗哮喘III期试验达到实验终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a85316e489c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947717, encodeId=3f22194e7172e, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=晚期非小细胞肺癌一线治疗新方法：TG4010+Nivolumab+化疗方案的II期试验, objectType=article, longId=167059, objectId=934c16e059fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=934c16e059fc, replyNumber=0, likeNumber=62, createdTime=2020-04-26, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=934c16e059fc, moduleTitle=晚期非小细胞肺癌一线治疗新方法：TG4010+Nivolumab+化疗方案的II期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=934c16e059fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947712, encodeId=34b5194e71238, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=尼古丁和烟草研究协会（SRNT）年会：I / II期试验阐明了Cytisinicline的多剂量、药代动力学和药效学特征, objectType=article, longId=161124, objectId=282916112457, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=282916112457, replyNumber=0, likeNumber=83, createdTime=2019-12-12, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=282916112457, moduleTitle=尼古丁和烟草研究协会（SRNT）年会：I / II期试验阐明了Cytisinicline的多剂量、药代动力学和药效学特征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=282916112457)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947709, encodeId=a37b194e70909, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=Bavarian Nordic完成了Chordoma II期试验治疗脊索瘤的患者入组, objectType=article, longId=159221, objectId=3ed915922106, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ed915922106, replyNumber=0, likeNumber=72, createdTime=2019-09-26, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ed915922106, moduleTitle=Bavarian Nordic完成了Chordoma II期试验治疗脊索瘤的患者入组, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ed915922106)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947715, encodeId=c71a194e715a2, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=2019年美国临床内分泌学家协会（AACE）大会：Teprotumumab治疗甲状腺眼病的III期试验结果, objectType=article, longId=164221, objectId=3dc6164221e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3dc6164221e6, replyNumber=0, likeNumber=69, createdTime=2019-11-01, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3dc6164221e6, moduleTitle=2019年美国临床内分泌学家协会（AACE）大会：Teprotumumab治疗甲状腺眼病的III期试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3dc6164221e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947707, encodeId=4383194e707ed, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=JCO：地塞瑞克与曲普瑞林治疗局部晚期内分泌反应性乳腺癌：随机II期试验, objectType=article, longId=157059, objectId=a02715e05966, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a02715e05966, replyNumber=0, likeNumber=66, createdTime=2019-03-17, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a02715e05966, moduleTitle=JCO：地塞瑞克与曲普瑞林治疗局部晚期内分泌反应性乳腺癌：随机II期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a02715e05966)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947708, encodeId=df61194e70897, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=Bardoxolone治疗常染色体显性多囊肾病的III期试验正式开始, objectType=article, longId=159160, objectId=1493159160dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1493159160dd, replyNumber=0, likeNumber=131, createdTime=2019-10-08, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1493159160dd, moduleTitle=Bardoxolone治疗常染色体显性多囊肾病的III期试验正式开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1493159160dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947711, encodeId=7793194e711d8, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=Ocaliva符合NASH引起的肝纤维化患者III期试验的主要目标, objectType=article, longId=160890, objectId=1e4416089059, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e4416089059, replyNumber=0, likeNumber=61, createdTime=2019-09-03, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e4416089059, moduleTitle=Ocaliva符合NASH引起的肝纤维化患者III期试验的主要目标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e4416089059)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947710, encodeId=4046194e71037, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=Lancet Gastroen Hepatol：慢性丙型肝炎抗病毒新药临床III期试验研究进展, objectType=article, longId=159965, objectId=41ba15996571, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41ba15996571, replyNumber=0, likeNumber=64, createdTime=2019-08-11, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41ba15996571, moduleTitle=Lancet Gastroen Hepatol：慢性丙型肝炎抗病毒新药临床III期试验研究进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41ba15996571)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947706, encodeId=9b04194e706bf, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=III期试验证明IL-23单抗Tildrakizumab在3年内对中度-严重慢性斑块状银屑病患者维持良好疗效和安全性, objectType=article, longId=149073, objectId=52291490e33c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52291490e33c, replyNumber=0, likeNumber=74, createdTime=2018-12-22, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52291490e33c, moduleTitle=III期试验证明IL-23单抗Tildrakizumab在3年内对中度-严重慢性斑块状银屑病患者维持良好疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=52291490e33c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947714, encodeId=3631194e714a7, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=Leber遗传性视神经病变的治疗或许不再是难题：GS010的REVERSE III期试验数据即将公布, objectType=article, longId=162523, objectId=00a21625233c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00a21625233c, replyNumber=0, likeNumber=62, createdTime=2019-11-17, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00a21625233c, moduleTitle=Leber遗传性视神经病变的治疗或许不再是难题：GS010的REVERSE III期试验数据即将公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=00a21625233c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947705, encodeId=7f72194e7051b, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=JCO：Pembrolizumab用于难治性或复发性胸腺上皮肿瘤患者：开放性II期试验, objectType=article, longId=140934, objectId=089b1409347d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=089b1409347d, replyNumber=0, likeNumber=61, createdTime=2019-05-30, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=089b1409347d, moduleTitle=JCO：Pembrolizumab用于难治性或复发性胸腺上皮肿瘤患者：开放性II期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=089b1409347d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947703, encodeId=3e93194e703f1, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=JCO：晚期乳头状肾细胞癌患者使用savolitinib的生物标志物（II期试验）, objectType=article, longId=103418, objectId=36731034183e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36731034183e, replyNumber=0, likeNumber=83, createdTime=2017-08-25, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36731034183e, moduleTitle=JCO：晚期乳头状肾细胞癌患者使用savolitinib的生物标志物（II期试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36731034183e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947702, encodeId=4b38194e70244, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=J CLIN ONCOL：塞来考昔联合标准化疗对环氧合酶-2过表达的晚期非小细胞肺癌的III期试验, objectType=article, longId=102867, objectId=c30f10286e18, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c30f10286e18, replyNumber=0, likeNumber=64, createdTime=2018-04-23, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c30f10286e18, moduleTitle=J CLIN ONCOL：塞来考昔联合标准化疗对环氧合酶-2过表达的晚期非小细胞肺癌的III期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c30f10286e18)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947704, encodeId=78fb194e70471, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=Tafamidis符合甲状腺素心肌病III期试验的主要目标, objectType=article, longId=134232, objectId=617013423247, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=617013423247, replyNumber=0, likeNumber=80, createdTime=2018-08-20, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=617013423247, moduleTitle=Tafamidis符合甲状腺素心肌病III期试验的主要目标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=617013423247)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947701, encodeId=8ecd194e7012a, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=Lancet Oncol：trastuzumab emtansine III期试验最终数据分析, objectType=article, longId=98926, objectId=79479892694, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=79479892694, replyNumber=0, likeNumber=66, createdTime=2018-04-09, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=79479892694, moduleTitle=Lancet Oncol：trastuzumab emtansine III期试验最终数据分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=79479892694)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947700, encodeId=b966194e700fc, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=细胞治疗传来喜讯：Kite Pharma发布KTE-C19临床II期试验部分结果，治疗侵袭性淋巴瘤的缓解率为76%，疗效明显, objectType=article, longId=90291, objectId=307e9029194, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=307e9029194, replyNumber=0, likeNumber=107, createdTime=2017-10-15, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=307e9029194, moduleTitle=细胞治疗传来喜讯：Kite Pharma发布KTE-C19临床II期试验部分结果，治疗侵袭性淋巴瘤的缓解率为76%，疗效明显, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=307e9029194)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947699, encodeId=1bf2194e69935, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=JCO：额外的伊匹单抗+化疗vs.单独化疗未能延长广泛性SCLC患者生存期(III期试验), objectType=article, longId=74272, objectId=147de42721f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=147de42721f, replyNumber=0, likeNumber=57, createdTime=2017-02-28, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=147de42721f, moduleTitle=JCO：额外的伊匹单抗+化疗vs.单独化疗未能延长广泛性SCLC患者生存期(III期试验), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=147de42721f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947698, encodeId=8789194e69809, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=捷报！Novavax呼吸道合胞病毒疫苗临床II期试验获喜人成果, objectType=article, longId=54770, objectId=b5cd54e7008, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b5cd54e7008, replyNumber=0, likeNumber=70, createdTime=2016-06-09, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b5cd54e7008, moduleTitle=捷报！Novavax呼吸道合胞病毒疫苗临床II期试验获喜人成果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b5cd54e7008)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

II期试验

2020-05-29

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

JCO：PROSTVAC在转移性去势抵抗性前列腺癌中的III期试验

2019-11-18

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

诺华的吸入型联合疗法QMF149治疗哮喘III期试验达到实验终点

2019-10-08

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

晚期非小细胞肺癌一线治疗新方法：TG4010+Nivolumab+化疗方案的II期试验

2020-04-26

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

尼古丁和烟草研究协会（SRNT）年会：I / II期试验阐明了Cytisinicline的多剂量、药代动力学和药效学特征

2019-12-12

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

Bavarian Nordic完成了Chordoma II期试验治疗脊索瘤的患者入组

2019-09-26

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

2019年美国临床内分泌学家协会（AACE）大会：Teprotumumab治疗甲状腺眼病的III期试验结果

2019-11-01

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

JCO：地塞瑞克与曲普瑞林治疗局部晚期内分泌反应性乳腺癌：随机II期试验

2019-03-17

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

Bardoxolone治疗常染色体显性多囊肾病的III期试验正式开始

2019-10-08

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

Ocaliva符合NASH引起的肝纤维化患者III期试验的主要目标

2019-09-03

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

Lancet Gastroen Hepatol：慢性丙型肝炎抗病毒新药临床III期试验研究进展

2019-08-11

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

III期试验证明IL-23单抗Tildrakizumab在3年内对中度-严重慢性斑块状银屑病患者维持良好疗效和安全性

2018-12-22

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

Leber遗传性视神经病变的治疗或许不再是难题：GS010的REVERSE III期试验数据即将公布

2019-11-17

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

JCO：Pembrolizumab用于难治性或复发性胸腺上皮肿瘤患者：开放性II期试验

2019-05-30

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

JCO：晚期乳头状肾细胞癌患者使用savolitinib的生物标志物（II期试验）

2017-08-25

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

J CLIN ONCOL：塞来考昔联合标准化疗对环氧合酶-2过表达的晚期非小细胞肺癌的III期试验

2018-04-23

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

Tafamidis符合甲状腺素心肌病III期试验的主要目标

2018-08-20

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

Lancet Oncol：trastuzumab emtansine III期试验最终数据分析

2018-04-09

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

细胞治疗传来喜讯：Kite Pharma发布KTE-C19临床II期试验部分结果，治疗侵袭性淋巴瘤的缓解率为76%，疗效明显

2017-10-15

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

JCO：额外的伊匹单抗+化疗vs.单独化疗未能延长广泛性SCLC患者生存期(III期试验)

2017-02-28

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

捷报！Novavax呼吸道合胞病毒疫苗临床II期试验获喜人成果

2016-06-09

科室
- - 订阅+
  - 更多科室
工具
服务